Berkeley Heights, NJ, October 31, 2002
- Genta Incorporated (NASDAQ: GNTA) announced it will hold a
conference call on Thursday, November 7, 2002 at 8:00 AM EST to
discuss third-quarter 2002 earnings and company highlights. Dr.
Raymond P. Warrell, Jr., Genta's Chairman and CEO, will host the
conference call.
The conference call can be accessed as follows:
U.S./Canada: Dial (888) 529-1867, reference
Genta
International: Dial (706) 643-1282, reference
Genta
Or via the web through Genta's investor site
at:
http://www.genta.com/Genta/InvestorRelation/events.html
A replay will be available after the completion of
the conference call and is accessible via streaming media through
the company's investor relations site at
http://www.genta.com/Genta/InvestorRelation/events.html
.
Genta Incorporated is a biopharmaceutical
company with a diversified product portfolio that is focused on
anticancer therapy. The Company's research platform is anchored by
DNA medicines, particularly applications of antisense and decoy
aptamer technology. GenasenseTM, the Company"s lead compound, has
received "Fast Track" and "Orphan Drug" designation from the Food
and Drug Administration. Genasense
TM
is currently undergoing late-stage, Phase 3 clinical testing in
several clinical indications. Genta's pipeline also comprises a
portfolio of small molecules, including gallium-containing
compounds and Androgenics compounds. Genta aims to become a direct
marketer of its pharmaceutical products in North America. For more
information about Genta, please visit our website at:
http://www.genta.com/
The statements contained in this press release that are not
historical are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended,
including statements regarding the expectations, beliefs,
intentions or strategies regarding the future. Without limiting
the foregoing, the words ``anticipates,"" ``believes,""
``expects,"" ``intends,"" ``may"" and ``plans"" and similar
expressions are intended to identify forward-looking statements.
The Company intends that all forward-looking statements be
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
reflect the Company"s views as of the date they are made with
respect to future events, but are subject to many risks and
uncertainties, which could cause the actual results of the
Company to differ materially from any future results expressed or
implied by such forward-looking statements. For example, the
results obtained in pre-clinical or clinical studies may not be
indicative of results that will be obtained in future clinical
trials, and delays in the initiation or completion of clinical
trials may occur as a result of many factors. Further examples of
such risks and uncertainties also include, but are not limited
to: the obtaining of sufficient financing to maintain the
Company"s planned operations; timely development, receipt of
necessary regulatory approvals, and acceptance of new products;
the successful application of the Company"s technology to produce
new products; the obtaining of proprietary protection for any
such technology and products; the impact of competitive products
and pricing and reimbursement policies; and changing market
conditions. The Company does not undertake to update forward-
looking statements. Although the Company believes that the
forward-looking statements contained herein are reasonable, it
can give no assurances that the Company"s expectations are
correct. All forward looking statements are expressly qualified
in their entirety by this cautionary statement and other factors
detailed in the Company"s reports filed with the Securities and
Exchange Commission.
SOURCE: Genta Incorporated
